Toronto, Monday 04 November 2019 12.00 CEST
A randomized controlled trial (RCT) showed that adding GAIA’s digital therapy software, deprexis, to standard inpatient hospital treatment improved remission rates among patients with severe depression. New analyses of that trial, which included 229 patients, demonstrated that these beneficial effects persist and may even grow stronger over time. At six months, nearly three times as many patients had achieved remission from depression if they had started deprexis during their hospital stay.
Similar effects were also shown on secondary outcomes, including reductions in anxiety and improvements in quality of life as well as self-esteem. These clinically significant effects once again demonstrate the potential of our products to function as potent catalysts of sustained therapeutic improvements. GAIA digital treatments can be easily integrated in a variety of settings, including inpatient hospital treatment and outpatient psychotherapy.
The study, led by Dr. Rüdiger Zwerenz and Professor Manfred Beutel at the University Medical Center Mainz, was published in the Journal of Medical Internet Research: https://www.jmir.org/2019/10/e13655/